Literature DB >> 28830209

Puerarin Improves Vascular Insulin Resistance and Cardiovascular Remodeling in Salt-Sensitive Hypertension.

Chunxiang Tan1, Aimei Wang1, Chan Liu2, Yao Li1, Yuepin Shi3, Ming-Sheng Zhou4.   

Abstract

Puerarin is an isoflavonoid isolated from the Chinese herb, Kudzu roots (also known as Gegen), which has been widely used for the treatment of hypertensive diseases and diabetic mellitus in traditional Chinese medicine. Dahl salt-sensitive (DS) rat is a genetic model of salt-sensitive hypertension with cardiovascular injury and vascular insulin resistance. Here, we investigated whether puerarin improved vascular insulin resistance and attenuated cardiac and aortic remodeling in salt-sensitive hypertension. DS rats were given a normal (NS) or high salt diet (HS) for five weeks. An additional group of DS rats was pretreated with puerarin and NS for 10 days, then switched to HS plus puerarin for five weeks. HS for five weeks increased systolic blood pressure (SBP), cardiac hypertrophy and fibrosis, and aortic hypertrophy with increased the expression of phosphor-ERK1/2 in the aorta and heart; puerarin attenuated cardiac and aortic hypertrophy, cardiac fibrosis and phosphor-ERK1/2 with a mild reduction in SBP. Hypertensive rats also manifested impairment of acetylcholine- and insulin-mediated vasorelaxation and insulin-mediated Akt and eNOS phosphorylation associated with the activation of NF[Formula: see text]B/TNF[Formula: see text]/JNK pathway. Puerarin improved acetylcholine- and insulin-mediated vasorelaxation and insulin-stimulated Akt/NO signaling with the inhibition of the NF[Formula: see text]B inflammatory pathway. Our results demonstrated that in salt-sensitive hypertension, puerarin improved vascular insulin action with cardiovascular beneficial effects. Our results found that the underlying mechanisms may involve its inhibition of NF[Formula: see text]B/JNK and ERK1/2 pathway. These results suggest that puerarin could be used as a new antihypertensive agent to expand our armamentarium for the prevention and treatment of end-organ damage in individuals with hypertension and metabolic diseases.

Entities:  

Keywords:  End Organ Damage; Hypertension; Pueraria lobata; Puerarin; Vascular Insulin Resistance

Mesh:

Substances:

Year:  2017        PMID: 28830209     DOI: 10.1142/S0192415X17500641

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  15 in total

1.  Puerarin prevents calcium oxalate crystal-induced renal epithelial cell autophagy by activating the SIRT1-mediated signaling pathway.

Authors:  Guan-Hua Jing; Ya-Dong Liu; Jian-Nan Liu; Yin-Shan Jin; Shi-Liang Yu; Rui-Hua An
Journal:  Urolithiasis       Date:  2022-08-01       Impact factor: 2.861

2.  Myeloid Angiotensin II Type 1 Receptor Mediates Macrophage Polarization and Promotes Vascular Injury in DOCA/Salt Hypertensive Mice.

Authors:  Xue-Feng Yang; Huan Wang; Yue Huang; Jian-Hua Huang; Hao-Lin Ren; Qian Xu; Xiao-Min Su; Ai-Mei Wang; Fu Ren; Ming-Sheng Zhou
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

3.  Nrf2 Is a Key Regulator on Puerarin Preventing Cardiac Fibrosis and Upregulating Metabolic Enzymes UGT1A1 in Rats.

Authors:  Shao-Ai Cai; Ning Hou; Gan-Jian Zhao; Xia-Wen Liu; Ying-Yan He; Hai-Lin Liu; Yong-Quan Hua; Li-Rong Li; Yin Huang; Cai-Wen Ou; Cheng-Feng Luo; Min-Sheng Chen
Journal:  Front Pharmacol       Date:  2018-06-06       Impact factor: 5.810

4.  Upregulation of UDP-Glucuronosyltransferases 1a1 and 1a7 Are Involved in Altered Puerarin Pharmacokinetics in Type II Diabetic Rats.

Authors:  Songtao Dong; Maofan Zhang; Huimin Niu; Kunyu Jiang; Jialei Jiang; Yinglin Ma; Xin Wang; Shengnan Meng
Journal:  Molecules       Date:  2018-06-20       Impact factor: 4.411

5.  Comparative Pharmacokinetic Profiles of Puerarin in Rat Plasma by UHPLC-MS/MS after Oral Administration of Pueraria lobata Extract and Pure Puerarin.

Authors:  Guozhe Zhang; Jianwei Ji; Mingzhong Sun; Yuqiao Ji; Hongjian Ji
Journal:  J Anal Methods Chem       Date:  2020-04-14       Impact factor: 2.193

6.  Puerarin alleviates osteoporosis in the ovariectomy-induced mice by suppressing osteoclastogenesis via inhibition of TRAF6/ROS-dependent MAPK/NF-κB signaling pathways.

Authors:  Long Xiao; Mengdan Zhong; Yu Huang; Jie Zhu; Wenkai Tang; Danyong Li; Jiandong Shi; Aiqing Lu; Huilin Yang; Dechun Geng; Hong Li; Zhirong Wang
Journal:  Aging (Albany NY)       Date:  2020-11-07       Impact factor: 5.682

Review 7.  The Potential Role of Flavonoids in Ameliorating Diabetic Cardiomyopathy via Alleviation of Cardiac Oxidative Stress, Inflammation and Apoptosis.

Authors:  Fatin Farhana Jubaidi; Satirah Zainalabidin; Izatus Shima Taib; Zariyantey Abd Hamid; Siti Balkis Budin
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

8.  Systems Pharmacology-Based Strategy to Investigate Pharmacological Mechanisms of Radix Puerariae for Treatment of Hypertension.

Authors:  Wenting Wu; Songhong Yang; Peng Liu; Li Yin; Qianfeng Gong; Weifeng Zhu
Journal:  Front Pharmacol       Date:  2020-03-24       Impact factor: 5.810

9.  Puerarin Relieved Compression-Induced Apoptosis and Mitochondrial Dysfunction in Human Nucleus Pulposus Mesenchymal Stem Cells via the PI3K/Akt Pathway.

Authors:  Donghua Huang; Yizhong Peng; Kaige Ma; Xiangcheng Qing; Xiangyu Deng; Zhiliang Li; Zengwu Shao
Journal:  Stem Cells Int       Date:  2020-01-11       Impact factor: 5.443

10.  Ameliorated biomechanical properties of carotid arteries by puerarin in spontaneously hypertensive rats.

Authors:  Xiaoxia Fang; Sheng Dong; Yun Wu; Yun He; Min Lu; Dandan Shi; Na Feng; Songhe Yin; Yan Jiang; Anhua Zhang; Yan Ding; Qiufang Zhang; Junming Tang; Wenjun Zhang; Xiju He
Journal:  BMC Complement Med Ther       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.